Compositions comprising Cyclosporin

1. An oral composition comprising cyclosporin, a hydrogel forming polymer matrix, a surfactant and an oil phase being dispersed in the hydrogel forming polymer matrix, wherein the oil phase comprises an oil and the surfactant, wherein the surfactant is present in an amount greater than the oil and in an amount of more than 6 wt % of the dry weight of the composition, wherein the surfactant is a combination of glyceryl monooleate and glyceryl dioleate; and wherein the hydrogel-forming polymer is in an amount of at least 25% by weight based upon the dry weight of the composition.

2. The composition of claim 1 wherein the oil phase comprises a solution of the cyclosporin.

3. The composition of claim 1 , wherein the oil comprises a liquid lipid, wherein the liquid lipid comprises a medium chain fatty acid triglyceride or a combination thereof, or the liquid lipid comprises a caprylic/capric triglyceride composition.

4. The composition of claim 1 , wherein the composition further comprises a solvent, wherein the solvent is miscible with the oil phase and water.

5. The composition of claim 1 , wherein the composition further comprises a high HLB surfactant having an HLB value of at least 10.

6. The composition of claim 4 , wherein the high HLB surfactant is selected from a fatty acid salt or a bile salt.

7. The composition of claim 1 , wherein the hydrogel forming polymer or hydrogel forming polymer matrix comprises a reversible hydrocolloid.

8. The composition of claim 1 , wherein the hydrogel forming polymer or hydrogel forming polymer matrix comprises a hydrocolloid selected from carrageenan, gelatin, agar and pectin, or a combination thereof.

9. The composition of claim 1 , wherein the composition is a solid composition and is formed by mixing an aqueous phase premix with an oil phase premix to form a mixture, the aqueous phase premix comprising the hydrogel forming polymer matrix and the oil phase premix comprising the oil phase in which the cyclosporin is dissolved and the surfactant.

10. The composition of claim 9 , wherein the composition further comprises a surfactant having an HLB value of at least 10 which is present in the aqueous phase premix.

11. The composition of claim 1 , wherein the composition is a solid composition and further comprises at least one coating.

12. The composition of claim 11 wherein the at least one coating is adapted to release the cyclosporin in at least the colon.

13. The composition of claim 12 wherein the coating comprises ethylcellulose.

14. The composition of claim 11 , wherein the at least one coating is present in an amount corresponding to a weight gain due to the coating of from 2% to 40%.

15. The composition of claim 11 , wherein the composition comprises two coatings, a first coating and a second coating.

16. The composition of claim 15 , wherein the first coating comprises a water-soluble cellulose ether and the second coating comprises ethylcellulose.

17. The composition of claim 16 , wherein the water-soluble cellulose ether is hydroxypropylmethyl cellulose.

18. The composition of claim 1 , wherein the composition is a solid composition that is in the form of a minibead having a size of from 0.5 mm to 5 mm.

19. A multiple mini bead formulation, comprising a unit dosage form comprising a multiplicity of mini beads of claim 18 .

20. The composition of claim 11 , wherein the composition provides a mean whole blood cyclosporin A AUC 0-inf of from about 140 to about 420 ng·hr/ml.

21. The composition of claim 11 , wherein the composition provides a C max of cyclosporin A of from about 15 to about 60 ng/ml.

22. The composition of claim 11 , wherein the time taken to reach maximum whole blood concentration of cyclosporin A following oral administration of a single dose of the composition (T max ) is between about 3 hours to about 10 hours.

23. The composition of claim 11 , wherein cyclosporin A absolute bioavailability following oral administration of the composition is less than 15%.

24. The composition of claim 11 , wherein the composition releases less than 15% of cyclosporin A after 2 hours; releases 10% to 40% of cyclosporin A at 4 hours; and releases from about 30% to 70% of cyclosporin A between 4 hours and 12 hours, when measured in a two stage dissolution test using a USP Apparatus II with a paddle speed of 75 rpm and a dissolution medium temperature of 37° C.; wherein for the first 2 hours of the dissolution test the dissolution medium is 750 ml of 0.1 N HCl, and at 2 hours 250 ml of 0.2M tribasic sodium phosphate containing 2% SDS is added to the dissolution medium and the pH is adjusted to pH 6.8.

25. The composition of claim 11 , wherein the composition provides a concentration of cyclosporin A in colonic tissue of at least 250 ng/g following oral administration of the composition to a human.

26. The composition of claim 25 , wherein the total daily dose of cyclosporin A administered to the human is in the range of from 1 mg to 500 mg.

27. The composition of claim 1 , further comprising a P450 inhibitor or a PgP inhibitor, or a combination thereof.

28. A pharmaceutical formulation comprising the composition of claim 1 .

29. The composition of claim 1 , wherein the surfactant is present in an amount of up to 20 wt % of the dry weight of the composition.

30. The composition of claim 1 , wherein the hydrogel-forming polymer is present in an amount of up to 70% by weight based upon the dry weight of the composition.

31. The composition of claim 1 , wherein the surfactant is present in an amount of more than 12 wt % of the oil phase.

32. The composition of claim 9 , wherein the surfactant is present in an amount of more than 12% of the oil phase.

33. The composition of claim 18 , wherein the surfactant is present in an amount of more than 12% of the oil phase.